Status:

UNKNOWN

COVID 19 ANTOBODIES IN PREGNANT WOMEN AND THEIR CONNECTION TO BETA CELL FUNCTION IN THE FETUS

Lead Sponsor:

Maaynei Hayesha Medical Center

Conditions:

Generation of Anti COVID-19 Antibodies in a Fetus, Whose Mother Was Exposed to COVID or Was Vaccinated During Pregnancy

Eligibility:

FEMALE

18-48 years

Brief Summary

The aim of this study is to check for the presence of COVID 19 antibodies \[Covid-19, GAD-65, IA-2, ICA\] in the blood of laboring women who have been exposed to either the virus itself or to the vacc...

Detailed Description

T1D is caused by an autoimmune reaction to proteins that cause the destruction of the pancreatic beta cells. The incidence of childhood Type 1 diabetes (T1D) is continuously increasing, caused by envi...

Eligibility Criteria

Inclusion

  • exposure to the COVID 19 virus or vaccine during pregnancy

Exclusion

  • \- Age under 18 or over 48 IUFD

Key Trial Info

Start Date :

April 26 2021

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

July 1 2022

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT04860908

Start Date

April 26 2021

End Date

July 1 2022

Last Update

April 27 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Maayanei Hayeshua Medical Center

Bnei Brak, Central District, Israel

COVID 19 ANTOBODIES IN PREGNANT WOMEN AND THEIR CONNECTION TO BETA CELL FUNCTION IN THE FETUS | DecenTrialz